


Identifying Atypical Hemolytic Uremic Syndrome in the Pregnancy-Postpartum Setting

A Guide To Differential Diagnosis

Identifying Atypical-HUS in the Pregnancy/Postpartum Setting

The information in this brochure is intended as educational information for healthcare professionals. It does not replace a healthcare professional's judgment or clinical diagnosis.

Differential Diagnosis of Atypical-HUS¹⁻⁴



TMA can also manifest in the presence of clinical conditions such as the following


- Pregnancy-postpartum
- Malignant/severe hypertension
- Solid organ transplantation
- Autoimmune disease (eg, SLE, scleroderma)
- Hematopoietic stem cell transplantation

^aShiga toxin/EHEC test is warranted with history/presence of GI symptoms. ^bRange found in published literature is $<5\%$ - 10% .

ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13; HUS, hemolytic uremic syndrome; CV, cardiovascular; eGFR, estimated glomerular filtration rate; EHEC, enterohemorrhagic *Escherichia coli*; GI, gastrointestinal; MI, myocardial infarction; sCr, serum creatinine; STEC-HUS, Shiga toxin-producing *Escherichia coli*-hemolytic uremic syndrome; SLE, systemic lupus erythematosus; TMA, thrombotic microangiopathy; TTP, thrombotic thrombocytopenic purpura.

Differential Diagnosis: Identifying Atypical-HUS in the Pregnancy-Postpartum Setting

- Thrombotic microangiopathy (TMA) is a serious medical condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and end-organ injury¹
- During pregnancy and the postpartum period, TMA can be caused by pregnancy-associated complications such as Hemolysis, Elevated Liver enzyme levels, and Low Platelet count (HELLP) syndrome or by other TMA disorders like atypical-HUS^{4,5}
 - In patients with complement dysregulation, normal pregnancy⁶ and pregnancy complications that activate the complement system, such as HELLP, may precipitate atypical-HUS or cause additional manifestations, resulting in persistent TMA despite treatment⁴
 - Atypical-HUS is a disease associated with the chronic risk of a complement-mediated TMA that can be unmasked during or after pregnancy⁴
- A diagnosis of atypical-HUS may be missed when a woman presents with a TMA during pregnancy because it can present with similar clinical features to HELLP⁵
 - Hemolysis is characteristic of both HELLP and atypical-HUS and hemolytic screening is essential to make a differential diagnosis⁵
- A high clinical suspicion for atypical-HUS should be raised if a woman presents with TMA during pregnancy along with the following characteristics
 - Renal dysfunction⁷
 - Hemolysis with⁵
 - Elevated LDH, specifically LDH >1000 U/L with serum creatinine (sCr) >1.1 mg/dL⁵
 - High LDH:AST ratio (>10:1) or low hemoglobin (<8 g/dL)⁵
 - sCr >2.0 g/dL or persistently elevated sCr >1.1 g/dL for >72 hours postpartum⁵
 - Elevated AST or ALT levels⁵
 - >25% decrease in platelet count from baseline⁵
 - Signs of persistent TMA more than 48 hours after delivery^{8,9}
 - Frequent presentation of TMA postpartum¹⁰⁻¹⁴
 - History of previous TMA^{10,11,15,16}
 - Family history of renal impairment or atypical-HUS^{11,16}
 - History of previous pregnancy-related complications¹⁰
- Timing of manifestation may identify patients with atypical-HUS
 - Atypical-HUS is a chronic disease, whereas symptoms of other pregnancy-associated conditions usually resolve within 24-48 hours of delivery⁷
 - 79% of cases of atypical-HUS unmasked by pregnancy have been described in the postpartum period¹⁰



A previous normal pregnancy does not exclude a diagnosis of atypical-HUS.¹⁰ If atypical-HUS or any TMA is suspected, involve a TMA expert in the diagnostic process.¹⁷

ALT, alanine aminotransferase; AST, aspartate aminotransferase; HELLP, Hemolysis, Elevated Liver enzyme levels, and Low Platelet count syndrome; HUS, hemolytic uremic syndrome; LDH, lactate dehydrogenase; sCr, serum creatinine; TMA, thrombotic microangiopathy TTP, thrombotic thrombocytopenic purpura.

Case Study^a

Patient Overview

- Female, aged 27 years, in the third trimester of pregnancy
- Presented to the emergency room with fatigue, nausea, vomiting, and upper right quadrant pain
- Lab results showed anemia, thrombocytopenia, and elevated AST, ALT, LDH and creatinine
- Family history of thrombotic thrombocytopenic purpura (TTP)

Clinical Presentation and Management

| | | | |
|---|--|--------------------------------|---|
| Fatigue, nausea, vomiting, and upper right quadrant pain TTP was excluded based on ADAMTS13 activity | Liver enzymes and platelets normalized | Premature delivery | Presented with thrombocytopenia, hemolysis, and kidney failure 6 months after HELLP diagnosis |
| First Hospital Admission | 5 days after PE/FFP | 14 days after discharge | Second Hospital Admission |
| Diagnosis: class 3 HELLP ^{14,a} Treatment: PE and FFP | Discharged from hospital | | Diagnosis: atypical-HUS |

ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13; FFP, fresh frozen plasma; HELLP, Hemolysis, Elevated Liver enzyme levels, and Low Platelet count syndrome; HUS, hemolytic uremic syndrome; PE, plasma exchange.

^aClass 1 HELLP, platelet count $<50 \times 10^9/L$ (severe thrombocytopenia); class 2 HELLP, platelet count between $50-100 \times 10^9/L$ (moderate thrombocytopenia); class 3 HELLP, platelet count between $100-150 \times 10^9/L$ (mild thrombocytopenia).¹⁴

Laboratory Values

| Laboratory Tests | Normal Values | At First Hospital Admission | 5 Days After FFP/PE | At Second Hospital Admission |
|--|---------------|-----------------------------|---------------------|------------------------------|
| Schistocytes | No | Yes | Yes | Yes |
| Platelet count, $\times 10^9/L$ | 150-450 | 121 | 218 | 118 |
| Lactate dehydrogenase, U/L | 100-190 | 260 | 200 | 269 |
| Hemoglobin, g/dL | 12.0-16.0 | 9.5 | 14.3 | 4.2 |
| Haptoglobin, mg/dL | 36-195 | 7.8 | 40 | 6.4 |
| Reticulocytes, % | 0.5-1.5 | 2.4 | 1.6 | 3.9 |
| Creatinine, mg/dL | 0.6-1.3 | 1.5 | 0.8 | 5.2 |
| Estimated glomerular filtration rate, mL/min/1.73 m ² | 90+ | 87 | 92.2 | 14.2 |
| Proteinuria | 0 | 1+ | 0 | 0 |
| Bilirubin, mg/dL | 0.0-0.3 | 5.8 | 0.1 | 6.2 |
| Alanine aminotransferase, IU/L | 7-56 | 662 | 54 | 24 |
| Aspartate aminotransferase, IU/L | 5-40 | 435 | 33 | 26 |
| Differential diagnosis evaluation | | | | |
| ADAMTS13 activity | $\geq 5\%$ | 63% | 63% | 63% |

ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13; FFP, fresh frozen plasma; IU, international unit; PE, plasma exchange.


Differential Diagnosis

- A diagnosis of atypical-HUS was made based on
 - The presence of TMA post-delivery and following discontinuation of PE
 - ADAMTS13 activity level that was $>5\%$, ruling out TTP as a cause of TMA

^aThe case described here is representative of physician experience and does not include actual patient data.

Important Considerations for a Differential Diagnosis

Differentiation of atypical-HUS from other TMAs and pregnancy-associated conditions is essential for optimal management decisions^{10,18}



ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13; aHUS, atypical hemolytic uremic syndrome; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BP, blood pressure; ESRD, end-stage renal disease; LDH, lactate dehydrogenase; HUS, hemolytic uremic syndrome; MAHA, microangiopathic hemolytic anemia PE, plasma exchange; SBP, systolic blood pressure; STEC, Shiga toxin-producing *Escherichia coli*; TMA, thrombotic microangiopathy; ULN, upper limit of normal.

Atypical-HUS is a disease associated with the chronic risk of complement-mediated TMA that can be unmasked during or after pregnancy⁴

A diagnosis of atypical-HUS may be missed during pregnancy because it can present with similar clinical features to HELLP⁵

If TMA is suspected it is important to include a multidisciplinary team of specialists in the diagnostic process¹⁷

HELLP, Hemolysis, Elevated Liver enzyme levels, and Low Platelet count syndrome; HUS, hemolytic uremic syndrome; TMA, thrombotic microangiopathy.

References

1. Goodship THJ, et al. *Kidney Int.* 2017;91:539-551.
2. Azoulay E, et al. *Chest.* 2017;152:424-434.
3. Laurence J, et al. *Clin Adv Hematol Oncol.* 2016;14:2-15.
4. Asif A, et al. *J Nephrol.* 2017;30:347-362.
5. Gupta M, et al. *Pregnancy Hypertens.* 2018;12:29-34.
6. Bruel A et al. *Clin J Am Soc Nephrol.* 2017;12:1237-1247.
7. Fang CJ, et al. *Br J Haematol.* 2008;143:336-348.
8. Dobyne A, et al. *Med J Obstet Gynecol.* 2015;3:1064.
9. Sibai BM, et al. *Am J Obstet Gynecol.* 1993;169:1000-1006.
10. Fakhouri F, et al. *J Am Soc Nephrol.* 2010;21:859-867.
11. De Sousa Amorim E, et al. *J Nephrol.* 2015;28:641-645.
12. English FA, et al. *Integr Blood Press Control.* 2015;8:7-12.
13. Mutter WP, Karumanchi SA. *Microvasc Res.* 2008;75:1-8.
14. Haram K, et al. *BMC Pregnancy Childbirth.* 2009;9:8.
15. Sellier-Leclerc AL, et al. *J Am Soc Nephrol.* 2007;18:2392-2400.
16. Barbour T, et al. *Nephrol Dial Transplant.* 2012;27:2673-2685.
17. Rivera MGU, et al. *PLoS One.* 2018;13:e0206558.
18. Saad AF, et al. *AJP Rep.* 2016;6:e125-e128.
19. Huerta A, et al. *Kidney Int.* 2018;93:450-459.
20. Goodship THJ, Kavanaugh D. *J Am Soc Nephrol.* 2010;21:731-732.